Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients

Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and... The effect of pioglitazone (PIO) on plasma adiponectin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) was studied in 11 type 2 diabetic patients (age, 52 ± 2 yr; body mass index, 29.6 ± 1.1 kg/m2; HbA1c, 7.8 ± 0.4%). HFC (magnetic resonance spectroscopy) and basal plasma adiponectin concentration were quantitated before and after PIO (45 mg/d) for 16 wk. Subjects received a 3-h euglycemic insulin (100 mU/m2·min) clamp combined with 3-[3H] glucose infusion to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO. PIO reduced fasting plasma glucose (10.0 ± 0.7 to 7.2 ± 0.6 mmol/liter, P < 0.01) and HbA1c (7.8 ± 0.4 to 6.5 ± 0.3%, P < 0.01) despite increased body weight (83.0 ± 3.0 to 86.4 ± 3.0 kg, P < 0.01). PIO improved Rd (6.6 ± 0.6 vs. 5.2 ± 0.5 mg/kg·min, P < 0.005) and reduced EGP (0.23 ± 0.04 to 0.05 ± 0.02 mg/kg·min, P < 0.01) during the 3-h insulin clamp. After PIO treatment, HFC decreased from 21.3 ± 4.2 to 11.0 ± 2.4% (P < 0.01), and plasma adiponectin increased from 7 ± 1 to 21 ± 2 μg/ml (P < 0.0001). Plasma adiponectin concentration correlated negatively with HFC (r = −0.60, P < 0.05) and EGP (r = −0.80, P < 0.004) and positively with Rd before (r = 0.68, P < 0.02) pioglitazone treatment; similar correlations were observed between plasma adiponectin levels and HFC (r = −0.65, P < 0.03) and Rd after (r = 0.70, P = 0.01) pioglitazone treatment. EGP was almost completely suppressed after pioglitazone treatment; taken collectively, plasma adiponectin concentration, before and after pioglitazone treatment, still correlated negatively with EGP during the insulin clamp (r = −0.65, P < 0.001). In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration. The increase in plasma adiponectin is strongly associated with a decrease in hepatic fat content and improvements in hepatic and peripheral insulin sensitivity. The increase in plasma adiponectin concentration after thiazolidinedione therapy may play an important role in reversing the abnormality in hepatic fat mobilization and the hepatic/muscle insulin resistance in patients with type 2 diabetes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients

Download PDF
7 pages

Loading next page...
 
/lp/oxford-university-press/decreased-plasma-adiponectin-concentrations-are-closely-related-to-8ISnlTO7Bm

References (53)

Publisher
Oxford University Press
Copyright
Copyright © 2004 by The Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
DOI
10.1210/jc.2003-031315
pmid
14715850
Publisher site
See Article on Publisher Site

Abstract

The effect of pioglitazone (PIO) on plasma adiponectin concentration, endogenous glucose production (EGP), and hepatic fat content (HFC) was studied in 11 type 2 diabetic patients (age, 52 ± 2 yr; body mass index, 29.6 ± 1.1 kg/m2; HbA1c, 7.8 ± 0.4%). HFC (magnetic resonance spectroscopy) and basal plasma adiponectin concentration were quantitated before and after PIO (45 mg/d) for 16 wk. Subjects received a 3-h euglycemic insulin (100 mU/m2·min) clamp combined with 3-[3H] glucose infusion to determine rates of EGP and tissue glucose disappearance (Rd) before and after PIO. PIO reduced fasting plasma glucose (10.0 ± 0.7 to 7.2 ± 0.6 mmol/liter, P < 0.01) and HbA1c (7.8 ± 0.4 to 6.5 ± 0.3%, P < 0.01) despite increased body weight (83.0 ± 3.0 to 86.4 ± 3.0 kg, P < 0.01). PIO improved Rd (6.6 ± 0.6 vs. 5.2 ± 0.5 mg/kg·min, P < 0.005) and reduced EGP (0.23 ± 0.04 to 0.05 ± 0.02 mg/kg·min, P < 0.01) during the 3-h insulin clamp. After PIO treatment, HFC decreased from 21.3 ± 4.2 to 11.0 ± 2.4% (P < 0.01), and plasma adiponectin increased from 7 ± 1 to 21 ± 2 μg/ml (P < 0.0001). Plasma adiponectin concentration correlated negatively with HFC (r = −0.60, P < 0.05) and EGP (r = −0.80, P < 0.004) and positively with Rd before (r = 0.68, P < 0.02) pioglitazone treatment; similar correlations were observed between plasma adiponectin levels and HFC (r = −0.65, P < 0.03) and Rd after (r = 0.70, P = 0.01) pioglitazone treatment. EGP was almost completely suppressed after pioglitazone treatment; taken collectively, plasma adiponectin concentration, before and after pioglitazone treatment, still correlated negatively with EGP during the insulin clamp (r = −0.65, P < 0.001). In conclusion, PIO treatment in type 2 diabetes causes a 3-fold increase in plasma adiponectin concentration. The increase in plasma adiponectin is strongly associated with a decrease in hepatic fat content and improvements in hepatic and peripheral insulin sensitivity. The increase in plasma adiponectin concentration after thiazolidinedione therapy may play an important role in reversing the abnormality in hepatic fat mobilization and the hepatic/muscle insulin resistance in patients with type 2 diabetes.

Journal

Journal of Clinical Endocrinology and Metabolism – Oxford University Press

Published: Jan 1, 2004

There are no references for this article.